摘要：

目的：探讨与比较奈达铂与顺铂联合紫杉醇治疗口腔癌的疗效。方法：选取2017年1月—2019年1月本院收治的口腔癌患者80例，依据随机表分为奈紫组（n=40）和顺紫组（n=40），奈紫组给予奈达铂联合紫杉醇治疗，顺紫组给予顺铂联合紫杉醇治疗，比较2组免疫功能[T淋巴细胞亚群（CD3⁺、CD4⁺、CD4⁺/CD8⁺）]、治疗疗效、不良反应及生存情况。结果：奈紫组和顺紫组经治疗后，CD3⁺、CD4⁺、CD4⁺/CD8⁺均明显高于治疗前，奈紫组经治疗后，CD3⁺、CD4⁺、CD4⁺/CD8⁺明显高于顺紫组，差异有统计学意义（P<0.05）；奈紫组不良反应发生率明显低于顺紫组，差异有统计学意义（P<0.05）；奈紫组的治疗有效率明显高于顺紫组，差异有统计学意义（P<0.05）；所有患者均获得随访、无失访病例，中位无进展生存时间为7个月、总生存时间11个月；奈紫组和顺紫组的1年生存率为87.5%、75.0%，2组比较，差异无统计学意义（P>0.05）。结论：与顺铂比较，奈达铂联合紫杉醇可有效改善口腔癌患者免疫功能及提高治疗疗效，有利于提高患者的生存质量，且安全性更高，但仍需进行进一步研究。

关键词: 奈达铂, 顺铂, 紫杉醇, 口腔癌, 疗效

Abstract:

Objective: To investigate and compare the therapeutic effects of nedaplatin-paclitaxel and cisplatin-paclitaxel in the treatment of oral cancer. Methods: A total of 80 patients with oral cancer in our hospital were selected from January 2017 to January 2019, and they were divided into two groups randomly: nedaplatin group(n=40) and cisplatin group (n=40). The nedaplatin group was treated with nedaplatin combined with paclitaxel, and the cisplatin group was treated with cisplatin combined with paclitaxel. The immune function [T lymphocyte subsets (CD3⁺, CD4⁺, CD4⁺/CD8⁺)], therapeutic effect, adverse reactions and survival rates of the two groups were compared. Results: The CD3⁺, CD4⁺, CD4⁺/CD8⁺ in the nedaplatin group and the cisplatin group after treatment were significantly higher than those before treatment, the CD3⁺, CD4⁺, CD4⁺/CD8⁺ in the nedaplatin group after treatment were significantly higher than those in the cisplatin group, the difference was statistically significant (P<0.05). The incidence of adverse reactions in the nedaplatin group were significantly lower than that in the cisplatin group, the difference was statistically significant(P<0.05). The effective rate of treatment in the nedaplatin group was significantly higher than that in the cisplatin group, the difference was statistically significant (P<0.05). All patients were followed up without loss of follow-up, and the median progression free survival time was 7 months and the total survival time was 11 months. The 1-year survival rate of nedaplatin group and cisplatin group was 87.5% and 75.0% respectively, there was no significant difference between the two groups(P>0.05). Conclusion: Compared with cisplatin, nedaplatin combined with paclitaxel can effectively improve the immune function and therapeutic effect of patients with oral cancer, it is helpful to improve the quality of life, and it has the higher safety, but it still needs further research.

Key words: nedaplatin, cisplatin, paclitaxel, oral cancer, curative effect